UPDATE: Needham On LivaNova Upgrade: Firm Highlights RECOVER Study As Major Potential Catalyst With A Potential Earlier Indication Of Success Than Expected; Expects ANTHEM-HFrEF Heart Failure Pivotal Trial To Cross 400 Patients With Follow-Up Data In 1Q21